Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH)’s share price traded down 1.7% during mid-day trading on Monday . The company traded as low as C$20.68 and last traded at C$20.78, 138,813 shares were traded during trading. A decline of 30% from the average session volume of 199,046 shares. The stock had previously closed at C$21.14.

The company has a debt-to-equity ratio of 2.22, a quick ratio of 20.43 and a current ratio of 21.01. The firm has a market cap of $2.41 billion and a price-to-earnings ratio of -16.01. The stock’s 50 day simple moving average is C$22.19 and its 200-day simple moving average is C$23.28.

Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last issued its quarterly earnings results on Thursday, May 14th. The company reported C($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of C($0.27) by C$0.07. The company had revenue of C$0.04 million for the quarter, compared to analyst estimates of C$0.08 million. On average, analysts expect that Aurinia Pharmaceuticals Inc will post -0.6 EPS for the current fiscal year.

In other Aurinia Pharmaceuticals news, Senior Officer Neil Solomons sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of C$21.11, for a total transaction of C$316,617.00. Following the transaction, the insider now owns 202,299 shares in the company, valued at approximately C$4,270,086.83.

Aurinia Pharmaceuticals Company Profile (TSE:AUP)

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: Buyback For Investors Defined

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with's FREE daily email newsletter.